Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Expert Discusses Venetoclax Potential in MCL

June 22nd 2018

Toby Eyre, MBChB, MRCP, discusses the results of the phase I study with venetoclax in patients with poor-risk relapsed/refractory mantle cell lymphoma.

Novel Targeted Antibody-Drug Conjugates in Non-Hodgkin Lymphoma

June 18th 2018

Antibody-drug conjugates represent a targeted class of agents with an improved therapeutic index over traditional chemotherapy in the treatment of non-Hodgkin lymphoma.

Tisagenlecleucel Demonstrates Durable Response Beyond 1 Year in DLBCL

June 17th 2018

At a median follow-up of 14.1 months, the chimeric antigen receptor T-cell therapy tisagenlecleucel achieved an objective response rate of 52% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

Polatuzumab Vedotin Plus BR Demonstrates Higher PET-CR in DLBCL

June 16th 2018

The addition of polatuzumab vedotin to bendamustine and rituximab induced a higher rate of complete responses by PET scan compared with BR alone in patients with relapsed/refractory diffuse large B-cell lymphoma.

Obinutuzumab/Chlorambucil Solidified as Frontline CLL Option

June 15th 2018

The combination of obinutuzumab and chlorambucil reduced the risk of death by 24% versus rituximab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.

Flinn Highlights Emerging Combos in Non-Hodgkin Lymphoma

June 15th 2018

Ian Flinn, MD, PhD, discusses the activity and tolerability of 5F9 with rituximab in relapsed/refractory non-Hodgkin lymphoma, as well as intriguing findings with ibrutinib/venetoclax in frontline chronic lymphocytic leukemia.

Update Sustains Liso-Cel as Strong Contender in CAR T-Cell Space

June 14th 2018

The CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (JCAR017; liso-cel) is showing promising response rates in patients with high-risk diffuse large B-cell lymphoma.

CAR T-Cell Therapy: The Sticker Price Is Just for Openers

June 12th 2018

CMS has proposed a different way to handle payment for chimeric antigen receptor T-cell therapy, one that the medical and manufacturing community thinks is unworkable.

Dr. Flinn Discusses Hu5F9-G4 Plus Rituximab in NHL

June 12th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses Hu5F9-G4 (5F9) plus rituximab (Rituxan) in patients with non-Hodgkin lymphoma.

Dr. Abramson Discusses TRANSCEND in Relapsed/Refractory B-Cell Lymphomas

June 8th 2018

Jeremy Slade Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the updated results of the TRANSCEND study in patients with relapsed/refractory b-cell lymphomas.

ASCO Studies Refine CAR T Cell Use

June 7th 2018

Several studies presented at the 2018 ASCO Annual Meeting helped further refine and inform treatment strategies for the budding class of CAR T-cell therapies, with a focus on predicting adverse events and optimizing efficacy.

Rituximab/Lenalidomide Potential Frontline Therapy for Follicular Lymphoma

June 4th 2018

Similar efficacy with the combination of rituximab and lenalidomide coupled with a better safety profile compared with rituximab plus chemotherapy may make the chemo-free regimen a new frontline option for patients with previously untreated follicular lymphoma.

Ibrutinib/Rituximab Reduces Progression Risk by 80% in Waldenstrom Macroglobulinemia

June 2nd 2018

Adding ibrutinib to rituximab lowered the risk of disease progression or death by 80% versus rituximab alone in patients with Waldenström macroglobulinemia.

Ofatumumab Combo Falls Short in Indolent Non-Hodgkin Lymphoma

May 25th 2018

Adding ofatumumab (Arzerra) to bendamustine (Treanda) failed to improve progression-free survival in patients with indolent B-cell non-Hodgkin lymphoma who did not respond to rituximab (Rituxan) monotherapy.

Expert Weighs Treatment Methods in Hodgkin Lymphoma

May 22nd 2018

Nilanjan Ghosh, MD, PhD, discusses the advances and ongoing research in frontline treatment of patients with Hodgkin lymphoma.

COG to Assess Targeted Therapies in a Variety of NHL Clinical Trials

May 5th 2018

The Children's Oncology Group is currently involved in 5 studies exploring targeted therapies in non-Hodgkin lymphoma (NHL) that could eventually change the face of pediatric NHL treatment.

2B8T2M Enhances exPBNK Expression, in Vitro Cytotoxicity in Rituximab-Sensitive/Resistant Burkitt Lymphoma

May 3rd 2018

2B8T2M, a fusion of the IL-15 superantagonist ALT-803, and 4 single-chains of rituximab (Rituxan) significantly boosted the cytotoxicity of expanded peripheral blood natural killer cells against Burkitt lymphoma cells in in vitro testing.

Promising Umbralisib Combinations Tested in NHL Subtypes

May 3rd 2018

The phase IIb UNITY-NHL clinical trial is exploring the novel drug umbralisib as monotherapy or as part of a doublet or a triplet. The doublet includes ublituximab and the triplet includes ublituximab and bendamustine.

Dr. Flinn on FDA Approval of Tisagenlecleucel in DLBCL

May 2nd 2018

Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.

Hamlin Discusses Practice-Changing Data in Lymphoma

April 25th 2018

Paul A. Hamlin, MD, discusses exciting updates from the 2017 ASH Annual Meeting throughout the large cell lymphoma space, as well as other advances on the horizon.